Latanoprost
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Latanoprost: From Glaucoma to Primary Hereditary Glaucoma
One-Sentence Summary
Latanoprost is a prostaglandin F2α analog used as a standard therapy to lower intraocular pressure in glaucoma and ocular hypertension. The TxGNN model predicts it may also be effective for Primary Hereditary Glaucoma, with 1 clinical trial currently supporting this direction and no published literature yet identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Glaucoma / ocular hypertension (standard latanoprost use; not confirmed in Taiwan license data — this product is not currently marketed in Taiwan) |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L2 |
| Taiwan Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
The formal original_moa field for this drug is currently a data gap. Based on the mechanistic information available in this evidence pack, latanoprost is an isopropyl ester prodrug of a PGF2α analog. After corneal esterase hydrolysis, the active acid form binds the FP receptor and increases uveoscleral (trabecular) outflow of aqueous humor, thereby lowering intraocular pressure — the established mechanism underlying prostaglandin analogs in glaucoma therapy.
Primary hereditary glaucoma (e.g., CYP1B1-associated congenital/juvenile-onset glaucoma) shares the same end-point pathology — elevated intraocular pressure — as the drug’s original indication, but arises from developmental abnormalities of the trabecular meshwork rather than the adult open-angle mechanism. Because the aqueous outflow pathway differs structurally in the hereditary form, extrapolating efficacy from adult open-angle glaucoma is mechanistically plausible but not automatic, and requires direct clinical confirmation rather than being treated as an already-approved use.
This is consistent with the identified trial evidence: a completed Phase 2 study specifically tested a prostaglandin analogue (drug class covering latanoprost) plus a carbonic anhydrase inhibitor in pediatric primary glaucoma refractory to surgery, but confirmation that latanoprost itself (rather than another class member) was the specific agent studied is still needed.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01527682 | Phase 2 | Completed | 37 | Assessed the ocular hypotensive effect and safety of a prostaglandin analogue (latanoprost) combined with dorzolamide in pediatric primary glaucoma refractory to surgery. |
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 2 RCT (n=37) supports the hypotensive efficacy and preliminary safety of a prostaglandin analogue in pediatric primary glaucoma, giving L2-level evidence for this prediction. However, the drug is not currently marketed in Taiwan and formal safety/label data are missing, so full approval cannot be recommended yet.
To proceed, the following is needed:
- TFDA package insert (warnings, contraindications) — currently a blocking data gap (DG001)
- Confirmed mechanism of action from DrugBank API — currently a high-priority data gap (DG002)
- Confirmation that NCT01527682 used latanoprost specifically, not another prostaglandin analogue
- Assessment of the Taiwan market entry/registration pathway, since the product currently holds 0 local licenses
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.